These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35188187)

  • 1. RAS and beyond: the many faces of the neurofibromatosis type 1 protein.
    Anastasaki C; Orozco P; Gutmann DH
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35188187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurofibromin - protein structure and cellular functions in the context of neurofibromatosis type I pathogenesis].
    Abramowicz A; Gos M
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1331-48. PubMed ID: 26671924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
    Feldkamp MM; Angelov L; Guha A
    Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
    Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
    Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
    Ratner N; Miller SJ
    Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
    J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
    Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
    Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
    Dasgupta B; Dugan LL; Gutmann DH
    J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromin and suppression of tumorigenesis: beyond the GAP.
    Mo J; Moye SL; McKay RM; Le LQ
    Oncogene; 2022 Feb; 41(9):1235-1251. PubMed ID: 35066574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of activation of the tumor suppressor protein neurofibromin.
    Chaker-Margot M; Werten S; Dunzendorfer-Matt T; Lechner S; Ruepp A; Scheffzek K; Maier T
    Mol Cell; 2022 Apr; 82(7):1288-1296.e5. PubMed ID: 35353986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights from animal models of neurofibromatosis type 1 cognitive impairment.
    Miller AH; Halloran MC
    Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 36037004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.
    Brown JA; Diggs-Andrews KA; Gianino SM; Gutmann DH
    Mol Cell Neurosci; 2012 Jan; 49(1):13-22. PubMed ID: 21903164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis 1: closing the GAP between mice and men.
    Dasgupta B; Gutmann DH
    Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.
    Shin J; Padmanabhan A; de Groh ED; Lee JS; Haidar S; Dahlberg S; Guo F; He S; Wolman MA; Granato M; Lawson ND; Wolfe SA; Kim SH; Solnica-Krezel L; Kanki JP; Ligon KL; Epstein JA; Look AT
    Dis Model Mech; 2012 Nov; 5(6):881-94. PubMed ID: 22773753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofibromatosis type 1 (NF1): diagnosis and management.
    Ferner RE; Gutmann DH
    Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
    Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
    Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.
    Patrakitkomjorn S; Kobayashi D; Morikawa T; Wilson MM; Tsubota N; Irie A; Ozawa T; Aoki M; Arimura N; Kaibuchi K; Saya H; Araki N
    J Biol Chem; 2008 Apr; 283(14):9399-413. PubMed ID: 18218617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.